NasdaqCM:AKTX

Stock Analysis Report

Executive Summary

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases.

Snowflake

Fundamentals

Moderate growth potential with worrying balance sheet.

Risks

  • Akari Therapeutics has significant price volatility in the past 3 months.
  • Akari Therapeutics is covered by less than 3 analysts.

Similar Companies

Share Price & News

How has Akari Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

NasdaqCM:AKTX

0.2%

US Pharmaceuticals

1.3%

US Market


1 Year Return

-6.4%

NasdaqCM:AKTX

-7.3%

US Pharmaceuticals

2.0%

US Market

AKTX outperformed the Pharmaceuticals industry which returned -7.5% over the past year.

AKTX underperformed the Market in United States of America which returned 1.7% over the past year.


Share holder returns

AKTXIndustryMarket
7 Day0%0.2%1.3%
30 Day-1.5%1.2%3.9%
90 Day-10.8%-3.6%3.4%
1 Year-6.4%-6.4%-5.0%-7.3%4.2%2.0%
3 Year-80.6%-80.6%12.2%4.4%47.2%37.6%
5 Yearn/a21.1%8.1%60.5%42.9%

Price Volatility Vs. Market

How volatile is Akari Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Akari Therapeutics undervalued based on future cash flows and its price relative to the stock market?


In this section, we usually try to help investors determine whether Akari Therapeutics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Akari Therapeutics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

Future Growth

How is Akari Therapeutics expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

66.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Unable to determine if Akari Therapeutics is high growth as no revenue estimate data is available.

Akari Therapeutics's earnings are expected to grow significantly at over 20% yearly.

Unable to compare Akari Therapeutics's revenue growth to the United States of America market average as no estimate data is available.

Akari Therapeutics's earnings growth is expected to exceed the United States of America market average.

Akari Therapeutics's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Akari Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Akari Therapeutics performed over the past 5 years?

0.2%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Akari Therapeutics does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.

Unable to compare Akari Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Akari Therapeutics's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Akari Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.


Return on Assets

It is difficult to establish if Akari Therapeutics has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Akari Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.


Next Steps

Financial Health

How is Akari Therapeutics's financial position?


Financial Position Analysis

Akari Therapeutics's short term (1 year) commitments are greater than its holdings of cash and other short term assets.

Akari Therapeutics has no long term commitments.


Debt to Equity History and Analysis

Akari Therapeutics has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.

Irrelevant to check if Akari Therapeutics's debt level has increased considering it has negative shareholder equity.


Balance Sheet

Low level of unsold assets.

Akari Therapeutics has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Akari Therapeutics has less than a year of cash runway based on current free cash flow.

Akari Therapeutics has less than a year of cash runway if free cash flow continues to reduce at historical rates of -3.8% each year.


Next Steps

Dividend

What is Akari Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Akari Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Akari Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Akari Therapeutics has not reported any payouts.

Unable to verify if Akari Therapeutics's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Akari Therapeutics has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Akari Therapeutics's salary, the management and board of directors tenure and is there insider trading?

3.7yrs

Average board tenure


CEO

Clive Richardson (54yo)

1.3yrs

Tenure

US$773,966

Compensation

Mr. Clive Richardson serves as the Chief Executive Officer of Akari Therapeutics, Plc since 2019. Mr. Richardson has been the Chief Operations Officer and Director of Akari Therapeutics, Plc since Septembe ...


CEO Compensation Analysis

Clive's remuneration is higher than average for companies of similar size in United States of America.

Clive's compensation has increased whilst company is loss making.


Board Age and Tenure

3.7yrs

Average Tenure

69yo

Average Age

The tenure for the Akari Therapeutics board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Ray Prudo (74yo)

    Executive Chairman

    • Tenure: 4yrs
    • Compensation: US$318.27k
  • Clive Richardson (54yo)

    COO, CEO & Director

    • Tenure: 1.3yrs
    • Compensation: US$773.97k
  • Miles Nunn

    Chief Scientific Officer

    • Tenure: 0yrs

Board Members

  • Don Williams (60yo)

    Director

    • Tenure: 3.3yrs
    • Compensation: US$78.65k
  • Ray Prudo (74yo)

    Executive Chairman

    • Tenure: 4yrs
    • Compensation: US$318.27k
  • Clive Richardson (54yo)

    COO, CEO & Director

    • Tenure: 1.3yrs
    • Compensation: US$773.97k
  • James Hill (73yo)

    Director

    • Tenure: 4yrs
    • Compensation: US$75.66k
  • Stuart Ungar (75yo)

    Director

    • Tenure: 4yrs
    • Compensation: US$65.36k
  • David Byrne (59yo)

    Director

    • Tenure: 3.4yrs
    • Compensation: US$65.36k
  • Michael Grissinger (65yo)

    Director

    • Tenure: 1.7yrs
    • Compensation: US$85.19k
  • Peter Feldschreiber (75yo)

    Director

    • Tenure: 1.7yrs
    • Compensation: US$85.19k

Company Information

Akari Therapeutics, Plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Akari Therapeutics, Plc
  • Ticker: AKTX
  • Exchange: NasdaqCM
  • Founded:
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$38.981m
  • Shares outstanding: 20.41m
  • Website: https://www.akaritx.com

Number of Employees


Location

  • Akari Therapeutics, Plc
  • 75/76 Wimpole Street
  • London
  • W1G 9RT
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AKTXNasdaqCM (Nasdaq Capital Market)YesSPON ADR EACH REPR 100 ORDUSUSDJun 2014
CLABDB (Deutsche Boerse AG)YesSPON ADR EACH REPR 100 ORDDEEURJun 2014

Biography

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases. Its  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/16 00:15
End of Day Share Price2019/09/13 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.